Allurion Technologies (ALUR) Preferred Stock Liabilities (2022 - 2024)
Allurion Technologies (ALUR) posted Preferred Stock Liabilities of $979000.0 for Q3 2024, down 98.31% on a QoQ basis from $58.0 million in Q2 2023.
Allurion Technologies (ALUR) Preferred Stock Liabilities (2022 - 2024) Analysis & Trends
Allurion Technologies' Preferred Stock Liabilities history runs 3 years deep, the most recent figure standing at $979000.0 for Q3 2024.
- Quarterly Preferred Stock Liabilities changed N/A year-over-year to $979000.0 in Q3 2024, while the trailing twelve-month figure through Sep 2024 was $979000.0 (changed N/A YoY) and the FY2022 annual result came in at $58.0 million, changed N/A from the prior year.
- Preferred Stock Liabilities was $979000.0 for Q3 2024 at Allurion Technologies, down from $58.0 million in the prior quarter.
- Across five years, Preferred Stock Liabilities topped out at $58.0 million in Q2 2023 and bottomed at $979000.0 in Q3 2024.
- A 3-year average of $39.0 million and a median of $58.0 million in 2022 frame the typical range for Preferred Stock Liabilities.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | - |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | - |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | - |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | - |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | - |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | - |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | - |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | - |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Allurion Technologies | 74.67 Mn | 69.62 Mn | 1.23 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 979,000.00 |
| Jun 30, 2023 | 58.03 Mn |
| Dec 31, 2022 | 58.00 Mn |